Nevertheless, we recommend prioritizing the use of PD-L1 antibodies over signaling inhibitors or cytokine-targeted therapies, as the latter could downregulate MICA/B, potentially compromising anti-tumor immunity. The gene discussed is CD274; the disease is neoplasm.